ProQR Therapeutics BV

PRQR.US
Healthcare · Biotechnology
1.76
+0.03 (+1.73%)
USD · NASDAQ

Company Information

Company Name
ProQR Therapeutics BV
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: NL0010872495
CIK: 0001612940
CUSIP: N71542109
Currency: USD
Full Time Employees: 186
Phone: 31 88 166 7000
Fiscal Year End: December
IPO Date: Sep 18, 2014
Description:

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Address:

Zernikedreef 9, Leiden, Netherlands, 2333 CK

People

Directors & Officers

Name Title Year Born
Mr. Daniel Anton de Boer Founder, CEO & Executive Director 1983
Dr. Gerard Platenburg Ph.D. Co-Founder, Chief Scientific Officer & Executive Director 1964
Mr. Dennis Hom Chief Financial Officer 1975
Ms. Sheila Sponselee Chief People & Operations Officer 1984
Ms. Sarah Cue Kiely Vice President of Investor Relations & Corporate Communications NA
Dr. Cristina Lopez Lopez M.D., Ph.D. Chief Medical Officer 1976
Ms. Sandra van der Kolk Junior Financial Controller NA

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Adage Capital Partners Gp LLC 6.25M Mar 31, 2026 4.43% $0.02 0.00%
Privium Fund Management B.V. 5.47M Mar 31, 2026 3.87% $1.84 2.04%
Aberdeen Group PLC 3.32M Mar 31, 2026 2.35% $0.01 12.41%
Affinity Asset Advisors, LLC 2.45M Mar 31, 2026 1.74% $0.21 0.00%
Sio Capital Management, LLC 1.95M Mar 31, 2026 1.39% $0.45 -9.68%
Dafna Capital Management LLC 1.57M Mar 31, 2026 1.11% $0.58 0.00%
Kynam Capital Management, LP 1.57M Mar 31, 2026 1.11% $0.16 0.00%
Ikarian Capital, LLC 1.49M Mar 31, 2026 1.06% $0.20 0.00%
Morgan Stanley - Brokerage Accounts 1.30M Mar 31, 2026 0.92% $0.00 -4.93%
Junked Platinum Investment Management Ltd 1.24M Mar 31, 2026 0.88% $0.50 0.00%
Two Sigma Investments LLC 918.86K Mar 31, 2026 0.65% $0.00 9.47%
Point72 Asset Management, L.P. 755.84K Mar 31, 2026 0.54% $0.00 -7.10%
Citadel Advisors Llc 703.32K Mar 31, 2026 0.50% $0.00 20.59%
Delaware Management Holdings Inc 620.00K Mar 31, 2026 0.44% $0.00 0.00%
Walleye Trading Advisors, LLC 607.53K Mar 31, 2026 0.43% $0.00 2.66%
M28 Capital Management LP 599.79K Mar 31, 2026 0.43% $1.81 -41.17%
Two Sigma Advisers, LLC 452.40K Dec 31, 2025 0.32% $0.00 97.90%
Monaco Asset Management 418.80K Mar 31, 2026 0.30% $0.13 -2.33%
BOOTHBAY FUND MANAGEMENT, LLC 355.28K Mar 31, 2026 0.25% $0.01 0.00%
UBS Group AG 305.26K Mar 31, 2026 0.22% $0.00 -61.73%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 abrdn World Healthcare 6.31M 4.47% ▲ 85.10% Jun 30, 2026
2 abrdn Life Sciences Investors 2.62M 1.86% ▲ 0.00% Jun 30, 2026
3 Beleggingsfonds Hoofbosch 800.00K 0.57% ▲ 0.00% Mar 31, 2026
4 Nomura Healthcare Fund Class I 620.00K 0.44% ▲ 0.00% May 31, 2026
5 Fidelity Nasdaq Composite Index 84.91K 0.06% ▲ 0.00% May 31, 2026
6 Xtrackers S&P 500 Swap ETF 1C 56.43K 0.04% ▼ 0.73% Dec 31, 2025
7 Xtrackers MSCI World Swap ETF 1C 51.59K 0.04% ▼ 0.63% Dec 31, 2025
8 Blackstone Alternative Multi-Strategy I 4.50K 0.00% ▲ 12.50% Sep 30, 2025
9 NT Quality Small Cap Core 1.62K 0.00% ▲ 0.00% Mar 31, 2026
10 Knights of Columbus U.S. All Cap Idx I 397.00 0.00% ▲ 0.00% May 31, 2026

Financial Highlights

Market Cap: $244.14M
EBITDA: $-45.36M
PEG Ratio: $0.00
Book Value: $0.41
Earnings/Share: $-0.49
Profit Margin: 0.00%
Operating Margin: -671.37%
ROA (TTM): -23.07%
ROE (TTM): -78.07%
Revenue (TTM): $13.64M
Revenue/Share (TTM): $0.13
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -57.10%

Valuation Metrics

Enterprise Value: $170.38M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 141.12M
Shares Float: 75.15M
% Insiders: 1,805.70%
% Institutions: 3,866.40%
Short % Float: 2.15%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$15.28M
Cost of Goods Sold
adjust
$-2.60M
Gross Profit
subtotal
$12.68M
SG&A
adjust
$-15.06M
R&D
adjust
$-40.72M
Operating Income
subtotal
$-42.15M
Other / Non-Operating Items
adjust
$1.64M
Net Income
subtotal
$-40.52M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PRQR.US!